Objectives: To determine the dependence of plasma leptin concentrations upon circulating noradrenaline (NA) and thyroid hormones (TH) in humans. Design: Cross-sectional study in 40 newly diagnosed untreated patients with primary thyroid disease, and 69 lean and obese euthyroid control subjects. Measurements: Plasma leptin, NA, free T3 (fT3) .1]; ANOVA, P`0.0001). Plasma NA was similar in all groups (P n.s.). In obese controls, TSH correlated with % body fat and leptin (r 0.67, r 0.61; P`0.001). Treatment of hypothyroidism (n 10) with T4 reduced leptin from 20. 8 [11.8 ± 31.6] to 12.9 [4.6 ± 21.2] (P 0.005) with no change in BMI. Conclusions: Thyroid status modi®es leptin secretion independently of adiposity and NA. The data suggest leptin ± thyroid interactions at hypothalamic and adipocyte level.
Introduction
It is established that catecholamines suppress leptin production from adipose tissue in animals, 1 and we previously con®rmed this ®nding in humans with isoprenaline. 2 In vivo, sympathetic nervous system (SNS) responses are regulated by TH, and it is also established that thyroid disease alters b-adrenoceptor sensitivity in adipocytes, 3 rather than NA secretion. In the present analysis, we investigated the relationship of plasma leptin to PTA activity in euthyroid and dysthyroid subjects, and then examined whether differences in adiposity or plasma NA explain the altered leptin levels in thyroid disease. 
Results
Leptin levels were highest in obese-euthyroid and hypothyroid subjects (median [inter quartile range] 31.5 [19.0 ± 48.0] and 19.2 [11.5 ± 31.5] ng ml 71 ), and lowest in lean-euthyroid and hyperthyroid subjects (6.6 [3.9 ± 14.4] and 8.9 [5.5 ± 11.1]; ANOVA, P`0.0001). Hypothyroid leptin levels did not differ from those of obese controls and those of hyperthyroid patients were similar to lean controls (both P NS). Plasma NA levels were similar in all groups (P n.s.). In obese controls, TSH correlated with % body fat (r 0.67; P`0.001) and leptin (r 0.61; P`0.001). In thyroid patients, thyroid status was the strongest determinant of plasma leptin. 11 hypothyroid patients were followed on T4 treatment until clinically and biochemically euthyroid. Treatment of 10 hypothyroid subjects with T4 reduced plasma leptin levels (from 20.8 [11.8 ± 31.6] to 12.9 [4.6 ± 21.2]; P 0.005) with no change in BMI. One patient was diabetic and required insulin during follow-up, and so was omitted from the analysis. (See Figure 1) .
Discussion
These data suggest that PTA activity in euthyroid subjects correlates with leptin secretion, consistent with nutritional regulation in which positive energy balance increases, and negative energy balance reduces, TSH secretion. Indeed, it has been shown that leptin up-regulates hypothalamic pro-TRH expression. 4 The data also support interaction between leptin and PTA, in which increased TH secretion suppresses leptin. This observation may imply that TH directly suppresses leptin Ð an interpretation consistent, with known effects of TH on adipocyte adrenoceptor sensitivity. 3 Adiposity did not appear to explain changes in leptin levels in thyroid patients, although this issue requires further study. It can be proposed, that, despite little or no alteration in plasma NA levels in dysthyroid states, adipose tissue adrenergic responsiveness is altered, accounting for the observed leptin changes in thyroid disease. 
